2-(7-methoxy-naphth-1-yl) propanamine | 259866-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(7-methoxy-naphth-1-yl) propanamine
• 英文别名: [2-(7-methoxy-1-naphthyl)propyl]amine；2-(7-Methoxynaphthalen-1-yl)propan-1-amine
• CAS: 259866-24-5
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: YRYWDHSQOVIBCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(7-methoxy-naphth-1-yl) propanamine 在 氨 、 lithium 、 叔丁醇 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 [2-(7-methoxy-5,8-dihydronaphthalen-1-yl)propyl]amine
  参考文献：
  名称：

  [EN] SUBSTITUTED BENZAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS
  [FR] COMPOSES A BASE DE BENZAMIDES SUBSTITUES EN TANT QU'ANTAGONISTES DE RECEPTEURS VR1

  摘要：

  本发明提供了式(I)的化合物：其中，R1代表(C1-C6)烷氧基，卤代(C1-C6)烷氧基；R2代表氢原子或(C1-C6)烷基；R3代表氢原子，(C1-C6)烷氧基或羟基；或该化合物的药学上可接受的酯或其药学上可接受的盐。这些化合物对于治疗哺乳动物中由VR1受体过度激活引起的疾病条件，例如疼痛等，非常有用。本发明还提供了包含上述化合物的药物组合物。

  公开号：

  WO2005095329A1
• 作为产物：
  描述：

  2-(7-甲氧基萘-1-基)乙腈 在 氢气 、 镍 、 sodium hydride 作用下， 以 ammonium hydroxide 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.5h， 生成 2-(7-methoxy-naphth-1-yl) propanamine
  参考文献：
  名称：

  Synthesis of β-Substituted Naphth-1-yl Ethylamido Derivatives as New Melatoninergic agonists

  摘要：

  Naphthalene melatoninergic ligands with alkyl groups (Me, Et, Pr, Bz) in the beta position of the ethylamido chain were synthesised. The affinity of the compounds for chicken brain melatonin receptors was evaluated using 2-[I-125]-iodomelatonin as the radioligand. An increase in the affinity was observed with the beta-methyl derivatives and the greatest increase was seen with the (-) enantiomers. The introduction of a 2- or 7-MeO group on the naphthalene ring and the lengthening (Et, Pr) of the alkylamido chain gave potent compounds such as (-)1h (K-i = 24 pM). The functional activity of these compounds was evaluated by the aggregation of melanophores in Xenopus laevis tadpoles. The potency to produce lightening of the skin of Xenopus laevis was related to the affinities values of the molecules at melatonin chicken brain receptors. The most potent ligands were found to be full agonists and compound 1h was 25 fold more potent than melatonin in this bioassay. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00236-9

文献信息

• Synthesis of β-Substituted Naphth-1-yl Ethylamido Derivatives as New Melatoninergic agonists
  作者：Monique Mathé-Allainmat、Marie Le Gall、Carole Jellimann、Jean Andrieux、Michel Langlois

  DOI：10.1016/s0968-0896(99)00236-9

  日期：1999.12

  Naphthalene melatoninergic ligands with alkyl groups (Me, Et, Pr, Bz) in the beta position of the ethylamido chain were synthesised. The affinity of the compounds for chicken brain melatonin receptors was evaluated using 2-[I-125]-iodomelatonin as the radioligand. An increase in the affinity was observed with the beta-methyl derivatives and the greatest increase was seen with the (-) enantiomers. The introduction of a 2- or 7-MeO group on the naphthalene ring and the lengthening (Et, Pr) of the alkylamido chain gave potent compounds such as (-)1h (K-i = 24 pM). The functional activity of these compounds was evaluated by the aggregation of melanophores in Xenopus laevis tadpoles. The potency to produce lightening of the skin of Xenopus laevis was related to the affinities values of the molecules at melatonin chicken brain receptors. The most potent ligands were found to be full agonists and compound 1h was 25 fold more potent than melatonin in this bioassay. (C) 1999 Elsevier Science Ltd. All rights reserved.
• [EN] SUBSTITUTED BENZAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES A BASE DE BENZAMIDES SUBSTITUES EN TANT QU'ANTAGONISTES DE RECEPTEURS VR1
  申请人：PFIZER JAPAN INC

  公开号：WO2005095329A1

  公开（公告）日：2005-10-13

  This invention provides a compound of the formula (I): wherein R1 represents a (C1-C6)alkoxy group, a halo(C1-C6)alkoxy group, R2 represents a hydrogen atom or a (C1-C6)alkyl group, and R3 represents a hydrogen atom, a (C1­-C6)alkoxy group or a hydroxy group; or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了式(I)的化合物：其中，R1代表(C1-C6)烷氧基，卤代(C1-C6)烷氧基；R2代表氢原子或(C1-C6)烷基；R3代表氢原子，(C1-C6)烷氧基或羟基；或该化合物的药学上可接受的酯或其药学上可接受的盐。这些化合物对于治疗哺乳动物中由VR1受体过度激活引起的疾病条件，例如疼痛等，非常有用。本发明还提供了包含上述化合物的药物组合物。